WHO hails COVID-19 vaccine news after Moderna's progress, but warns there's 'no time for complacency'

WHO chief Tedros Adhanom Ghebreyesus warned that widespread availability of any vaccine remains a long way off, amid rising COVID-19 cases and deaths across the world

Agence France-Presse November 17, 2020 07:56:32 IST
WHO hails COVID-19 vaccine news after Moderna's progress, but warns there's 'no time for complacency'

File image of WHO chief Tedros Adhanom Ghebreyesus. Image: Salvatore di Nolfi/EPA

Geneva: Reported breakthroughs in COVID-19 vaccine research are "encouraging", the World Health Organization's chief said on Monday, but voiced concern about surging cases and warned against complacency.

"We continue to receive encouraging news about COVID-19 vaccines," WHO chief Tedros Adhanom Ghebreyesus told a virtual press briefing.

Tedros, who has just spent more than two weeks in quarantine after coming in contact with someone with COVID-19 , said he was "cautiously optimistic" that new tools would start to arrive in the coming months.

But he added: "This is no time for complacency."

His comments came as hopes trials of a second candidate vaccine suggested it was nearly 95 percent effective against the virus.

The news from US biotech firm Moderna followed similar interim results last week for Pfizer and BioNTech's candidate vaccine.

Playing with fire

But WHO has warned that widespread availability of any vaccine remains a long way off, and COVID-19 cases and deaths are surging in many parts of the world.

"Those countries that are letting the virus run unchecked are playing with fire," he said.

He voiced particular alarm about the situation in Europe and America, where he said health workers and systems were being pushed to breaking point.

"A laissez-faire attitude to the virus ... leads to death, suffering and hurts livelihoods and economies," he said.

"The quickest way to open up economies is to defeat the virus."

The UN agency's headquarters is experiencing its own outbreak of coronavirus , with Tedros spending 17 days in quarantine -- though he said he had not developed any symptoms.

Five new cases within the same WHO team have been registered in the past week, WHO official Maria Van Kerkhove said.

"We don't know if there is an actual cluster," she said, adding that experts were trying to work out if transmission had happened on the premises.

WHO emergencies director Michael Ryan stressed that the Geneva region is experiencing "some of the most intense transmission in the world right now".

"We are human beings and we live within a society," he said.

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Pfizer says its COVID-19 vaccine safe and 95% effective; to seek emergency use approval 'in days'
World

Pfizer says its COVID-19 vaccine safe and 95% effective; to seek emergency use approval 'in days'

The company didn’t disclose safety details but said no serious side effects have been reported, with the most common problem being fatigue after the second vaccine dose, affecting about four percent of participants

India in talks with Moderna over COVID-19 vaccine development after biotech firm says its candidate shows 95% efficacy
India

India in talks with Moderna over COVID-19 vaccine development after biotech firm says its candidate shows 95% efficacy

'We are also in dialogue with Pfizer, Serum Institute, Bharat Biotech and Zydus Cadila for their vaccine candidate in terms of safety, immunogenicity and efficacy,' a government official said

As race to COVID-19 vaccine heats up, a look at major jabs, development and clinical trials underway
India

As race to COVID-19 vaccine heats up, a look at major jabs, development and clinical trials underway

According to WHO, there are 48 COVID-19 vaccine candidates are undergoing clinical evaluation, of which eleven are at late-stage trials, whereas, 164 candidate vaccines are in preclinical evaluation